PharmaVentures appoints senior director
Paul Phull will develop corporate advisory business
PharmaVentures is an international corporate advisory firm supporting its clients’ growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisers, investment companies and government bodies.
Phull joins the company from Sinclair Pharma, a specialist pharmaceutical company in the UK, where he was responsible for the development of the international business. He has significant deal making and corporate transaction experience with a broad range of companies in Europe, US, Japan, India and Asia in a number of therapeutic areas.
You may also like
Finance
Moderna partners with Recordati to commercialise propionic acidemia mRNA therapy
The pair have entered a strategic collaboration to advance and globally commercialise its investigational propionic acidemia treatment mRNA-3927, with Moderna leading clinical development and manufacturing and Recordati responsible for worldwide commercialisation
Finance
AstraZeneca strengthens weight management pipeline with CSPC Pharmaceuticals collaboration
The pair have signed a strategic collaboration covering eight obesity and type 2 diabetes programmes, including a clinical-ready GLP-1/GIP asset, AI-driven peptide discovery capabilities and injectable dosing technology
Finance
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035